Multiparametric Flow Cytometry in the Evaluation of Plasma Cell Proliferative Disorders: Current Paradigms for Clinical Practice
Clinical Lymphoma Myeloma and Leukemia · 2024
DOI: 10.1016/j.clml.2023.11.006 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2024. Verfasst von Ritu Gupta und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Oncology, Dr. BRAIRCH, AIIMS, New Delhi, India; Department of Hematology, Mayo Clinic, Rochester, MN. Electronic address: dr…. Hauptthemen laut MEDLINE: Multiple Myeloma, Paraproteinemias. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 78 Literaturangaben. Gefördert von: Indian Council of Medical Research.
Abstract (Originalsprache)
Diagnosis of plasma cell proliferative disorders (PCPDs) is primarily based on the demonstration of monoclonal protein (M-Protein) in blood and/ or urine which often precedes clinical manifestations of the disease. The basic pathophysiology behind the M-protein presence is the proliferation of clonal plasma cells (PCs) in bone marrow or extramedullary sites and is assessed using cytomorphology and immunophenotyping. The role of multiparametric flow cytometry (MFC) for PC identification is technically the most valuable tool in this context as it characterizes as well as quantifies the clonal PCs based on differential expression of various immunophenotypic (IPT) markers. From a diagnostic perspective, MFC is critical in the definite identification of the clonal PCs and delineates benign and borderline entities at one end of the spectrum (MGUS, SMM) with lower clonal PC% and, malignant diseases at the other end (MM and PCL) with higher clonal PC fraction. The role of MFC in assessment of measurable residual disease (MRD) and monitoring of progression in MM and various PCPDs has been validated in multiple clinical studies and is probably one of the most promising tools for predicting treatment outcomes. Furthermore, MFC also plays a crucial role in disease prognostication based on specific IPT profiles. An additional role of MFC in the current clinical scenario is the evaluation of tumor microenvironment based on immune cell repertoire, which is reflecting encouraging results across. Thus, in the current review we concisely describe the role of MFC as a reliable and essential modality in PCPDs, from diagnosis to prediction of treatment outcome and disease monitoring.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Laboratory Oncology, Dr. BRAIRCH, AIIMS, New Delhi, India; Department of Hematology, Mayo Clinic, Rochester, MN. Electronic address: drritugupta@gmail.com.
- Department of Laboratory Medicine & Pathology, Mayo Clinic, Rochester, MN.
- Department of Hematology, Mayo Clinic, Rochester, MN.
Förderung
- Indian Council of Medical Research
Zitieren
APA
Gupta, R., Jevremovic, D., Mathew, S. J., & Kumar, S. (2024). Multiparametric Flow Cytometry in the Evaluation of Plasma Cell Proliferative Disorders: Current Paradigms for Clinical Practice. Clinical Lymphoma Myeloma and Leukemia. https://doi.org/10.1016/j.clml.2023.11.006
Vancouver
Gupta R, Jevremovic D, Mathew SJ, Kumar S. Multiparametric Flow Cytometry in the Evaluation of Plasma Cell Proliferative Disorders: Current Paradigms for Clinical Practice. Clinical Lymphoma Myeloma and Leukemia. 2024. doi:10.1016/j.clml.2023.11.006
BibTeX
@article{Gupta2024,
author = {Gupta, Ritu and Jevremovic, Dragan and Mathew, Smith J and Kumar, Shaji},
title = {Multiparametric Flow Cytometry in the Evaluation of Plasma Cell Proliferative Disorders: Current Paradigms for Clinical Practice},
journal = {Clinical Lymphoma Myeloma and Leukemia},
year = {2024},
doi = {10.1016/j.clml.2023.11.006}
}
EUVIMED